Yoo-Young Lee
성균관대학교 의과대학 · 의학
이 교수의 연구실은 자궁경부암의 생물학적 마커와 치료 반응 예측을 위한 생체지표 개발에 초점을 맞추고 있으며, 특히 전치료 NLR(백혈구/적혈구 비율)이 재발 및 사망 위험을 효과적으로 예측할 수 있는 지표임을 규명하고 있습니다. 또한, 방사선 치료와의 조합 효과를 극대화하기 위해 Wee1 억제제(AZD1775)와 방사선의 병용 치료 전략에 대한 기초 및 임상적 연구를 진행하고 있습니다. 최근에는 자궁경부암, 난소암, 자궁체암 등 여성종양의 임상 연구 동향을 종합적으로 분석하며, 표적치료제와 면역검사제 억제제의 임상적 응용 가능성도 탐색하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Pretreatment NLR may be a cost-effective biomarker to stratify risk of recurrence and death in patients with cervical cancer.
In 2020 series, we summarized the major clinical research advances in gynecologic oncology with providing representative figures of the most influential study for 1 of each 3 gynecologic cancers: cervix, ovary, and uterine corpus. Review for cervical cancer covered targeted agents and immune checkpoint inhibitors, adjuvant radiation therapy or concurrent/sequential chemoradiation therapy after radical hysterectomy in early cervical cancer, radical surgery in early cervical cancer; and prevention
Dynamin 2 is known as a protein involved in cell migration and endocytosis. We aimed to investigate the association between dynamin 2 expressions and tumor progression in early cervical carcinoma (IB1-IIA). Dynamin 2 expression was evaluated at protein level in thirty seven paraffin-embedded, formalin-fixed tissues including four normal cervix tissues and compared with pathologic risk factors for recurrence after surgery in thirty three patients with squamous cell carcinoma of the cervix. The ex
Targeting dynamin 2 may be a promising new approach for the treatment of cervical cancer.
We found that platinum-based combination chemotherapy during adjuvant CCRT after surgery promoted better survival than a weekly cisplatin regimen in ECC patients with pelvic LN metastasis.
In this study, the addition of adjuvant treatment was associated with an OS benefit for patients with LVSI, especially those with grade 3 endometrioid tumors.
